What type of study is this?

Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade

View Full Paper

Ask AI

Bookmark

Authors

Preclinical analysis demonstrates NDI-101150 enhances immune cell function, suggesting novel immunotherapy potential.

Treatment with NDI-101150 significantly enhances immune cell activation and reduces tumor growth in multiple models.
NDI-101150 activates T-cells and augments B-cell function, leading to effective antitumor responses even in resistant tumors.
Combining NDI-101150 with anti-PD-1 therapy shows potential for improved tumor response and immune memory.
HPK1 inhibition represents a promising therapeutic strategy for enhancing anti-tumor immunity across various conditions.

Ciccone et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark